INT14503

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1983
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 3.95
Pain Relevance 1.85

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (BCHE) extracellular region (BCHE) endoplasmic reticulum (BCHE)
enzyme binding (BCHE)
Anatomy Link Frequency
muscle 1
brain 1
BCHE (Homo sapiens)
Pain Link Frequency Relevance Heat
local anesthetic 2 99.80 Very High Very High Very High
antidepressant 7 97.24 Very High Very High Very High
Neuropeptide 3 92.88 High High
Central nervous system 12 92.60 High High
substance P 6 91.36 High High
Endep 7 91.28 High High
Enkephalin 5 90.36 High High
Potency 3 90.12 High High
Bioavailability 4 85.68 High High
fluoxetine 6 76.40 Quite High
Disease Link Frequency Relevance Heat
Amyloid Plaque 5 99.76 Very High Very High Very High
Dementia 26 99.74 Very High Very High Very High
Disease 127 99.64 Very High Very High Very High
Ocular Toxicity (including Many Sub-types) 1 98.76 Very High Very High Very High
Targeted Disruption 110 98.32 Very High Very High Very High
Cognitive Disorder 134 96.92 Very High Very High Very High
Alzheimer's Dementia 63 96.66 Very High Very High Very High
Toxicity 14 95.92 Very High Very High Very High
Anxiety Disorder 10 77.96 Quite High
Death 6 70.52 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The interaction of sertraline with the cholinesterase is labile since the removal of inhibitor by gel filtration recovered completely the enzyme activity.
cholinesterase Binding (interaction) of
1) Confidence 0.48 Published 2002 Journal Biochim. Biophys. Acta Section Abstract Doc Link 12009429 Disease Relevance 0 Pain Relevance 0.90
During the past 2 decades only 3 drugs for AD have been formally approved by the FDA, although in many countries there are several drugs which are currently used as neuroprotecting agents in dementia alone or in combination with cholinesterase inhibitors.
cholinesterase Binding (combination) of associated with dementia and alzheimer's dementia
2) Confidence 0.37 Published 2000 Journal Drugs Today Section Abstract Doc Link 12861345 Disease Relevance 0.88 Pain Relevance 0.04
Monoclonal antibodies allow precipitation of esterasic but not peptidasic activities associated with butyrylcholinesterase.
butyrylcholinesterase Binding (associated) of
3) Confidence 0.35 Published 1990 Journal J. Neurochem. Section Title Doc Link 1696618 Disease Relevance 0 Pain Relevance 0.36
Several cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and one glutamatergic neurotransmission modulator (memantine) are officially recognized as beneficial for patients with AD.
cholinesterase Binding (recognized) of
4) Confidence 0.35 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654526 Disease Relevance 1.09 Pain Relevance 0.20
Purified human serum butyrylcholinesterase, which exhibits cholinesterase, aryl acylamidase, and peptidase activities, was cross-reacted with two different monoclonal antibodies raised against human serum butyrylcholinesterase.
butyrylcholinesterase Binding (cross-reacted) of
5) Confidence 0.33 Published 1993 Journal J. Protein Chem. Section Abstract Doc Link 8427627 Disease Relevance 0 Pain Relevance 0.06
Therefore, we assume that benoxinate is metabolized by human pseudocholinesterase (PCHE, E.C. 3.1.1.8) and that ocular side effects after benoxinate application may be caused by altered metabolism of this drug, depending on genetically determined variants of pseudocholinesterase.
pseudocholinesterase Binding (metabolized) of associated with ocular toxicity (including many sub-types)
6) Confidence 0.32 Published 1983 Journal Metab Pediatr Syst Ophthalmol Section Abstract Doc Link 6621359 Disease Relevance 0.10 Pain Relevance 0.06
However, cholinesterase does not have the structural features suitable for binding with arsenic.
cholinesterase Binding (binding) of
7) Confidence 0.31 Published 2010 Journal Environ Health Section Body Doc Link PMC2911418 Disease Relevance 0.12 Pain Relevance 0
The "atypical" allelic variant of human butyrylcholinesterase (BuChE) can be characterized by its failure to bind the local anesthetic dibucaine, the muscle relaxant succinylcholine, and the naturally occurring steroidal alkaloid solanidine, all assumed to bind to the charged anionic site component within the normal BuChE enzyme.
butyrylcholinesterase Binding (bind) of in muscle associated with local anesthetic
8) Confidence 0.26 Published 1990 Journal J. Neurosci. Res. Section Abstract Doc Link 2079709 Disease Relevance 0 Pain Relevance 0.10
Cholinesterase inhibitors vary widely in their pharmacological profiles and affinities for AChE and butyrylcholinesterase.
butyrylcholinesterase Binding (affinities) of
9) Confidence 0.19 Published 2007 Journal Current Genomics Section Body Doc Link PMC2647161 Disease Relevance 0.11 Pain Relevance 0
BChE: butyrylcholinesterase; FVB: friend virus B-type; hSA: human serum albumin; huBChE: human butyrylcholinesterase; OP: organophosphorus compounds.


butyrylcholinesterase Binding (compounds) of
10) Confidence 0.18 Published 2008 Journal BMC Biotechnol Section Body Doc Link PMC2415180 Disease Relevance 0.38 Pain Relevance 0
BChE: butyrylcholinesterase; FVB: friend virus B-type; hSA: human serum albumin; huBChE: human butyrylcholinesterase; OP: organophosphorus compounds.


butyrylcholinesterase Binding (compounds) of
11) Confidence 0.15 Published 2008 Journal BMC Biotechnol Section Body Doc Link PMC2415180 Disease Relevance 0.45 Pain Relevance 0
Unlike the cholinesterase inhibitors, which indirectly and competitively antagonize NMBAs by increasing acetylcholine (ACh), sugammadex acts by directly encapsulating, binding, and inactivating NMBAs (Figure 1).


cholinesterase Binding (binding) of
12) Confidence 0.09 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761174 Disease Relevance 0 Pain Relevance 0
The evidence is as follows; both human acetylcholinesterase (hAChE) and butyrylcholinesterase (hBuChE) are associated with senile plaques and both the pattern of hAChE oligomerisation and its enzymatic activity are altered in brain areas affected by AD [12], [13], [16], [14], [17].
butyrylcholinesterase Binding (associated) of in brain associated with disease and amyloid plaque
13) Confidence 0.03 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1920558 Disease Relevance 0.82 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox